• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician

    2021-04-01 09:13:16JllioMariaFonsecaChebliNataliaSousaFreitasQueirozAdersonOmarMouraoCintraDamiaoLilianaAndradeChebliMarciaHenriquesdeMagalhaesCostaRogerioSerafimParra
    World Journal of Gastroenterology 2021年11期

    Jllio Maria Fonseca Chebli, Natalia Sousa Freitas Queiroz, Aderson Omar Mourao Cintra Damiao, Liliana Andrade Chebli, Marcia Henriques de Magalhaes Costa, Rogerio Serafim Parra

    Abstract Managing inflammatory bowel disease (IBD) during the coronavirus disease 2019 (COVID-19) pandemic has been a challenge faced by clinicians and their patients, especially concerning whether to proceed with biologics and immunosuppressive agents in the background of a global outbreak of a highly contagious new coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2). The knowledge about the impact of this virus on patients with IBD, although it is still scarce, is rapidly evolving. In particular, concerns surrounding medications’ impact for IBD on the risk of acquiring SARS-CoV-2 infection or developing COVID-19, and potentially exacerbate viral replication and the COVID-19 course, are a current thinking of both practicing clinicians and providers caring for patients with IBD. Managing patients with IBD infected with SARS-CoV-2 depends on both the clinical activity of the IBD and the occasional development and severity of COVID-19. In this review, we summarize the current data regarding gastrointestinal involvement by SARS-CoV-2 and pharmacologic and surgical management for IBD concerning this infection, and the COVID-19 impact on both the patient's psychological functioning and endoscopy services, and we concisely summarize the telemedicine roles during the COVID-19 pandemic.

    Key Words: Inflammatory bowel disease; SARS-CoV-2; COVID-19; Crohn disease; Colitis ulcerative; Biological therapy

    INTRODUCTION

    Over the past year, the coronavirus disease 2019 (COVID-19) pandemic has evolved as a public health emergency of international concern. The epidemiological panorama is constantly evolving, and the data updated to January 12, 2021 have 191 countries involved, with more than 90947243 confirmed cases and 1947243 confirmed deaths globally[1]. The first opportunity to eradicate the virus over the long term and to protect specific patients from COVID-19 is by introducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines[2]. Although efforts to implement mass vaccination programs are currently in place globally, high rates of COVID-19 infections and fatalities are still expected in the months ahead.

    Inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn’s disease (CD), are chronic inflammatory conditions of the gastrointestinal (GI) tract affecting millions of people worldwide[3]. Patients with IBD and other immunemediated diseases often require treatment with corticosteroids, immunomodulators (thiopurines, methotrexate), biologics, and Janus kinase inhibitors, which can increase the risk of infections[4-6]. However, until now, the incidence of SARS-CoV-2 infection in patients with IBD and immunosuppressive therapy did not appear to differ from the general population[7]. Also, based on data from an international registry developed to collect information from patients with IBD from all over the world with confirmed COVID-19 and its outcomes, and the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD), the evolution of COVID-19 does not seem to be worse in patients with IBD[8].

    Notwithstanding, most elective clinical activities involving IBD care were drastically decreased during the pandemic[9-11]. Moreover, as suggested by the most qualified international societies and organizations, outpatient visits, colonoscopies, and nonurgent surgery have been postponed to prevent patient contact with the hospital and to enable patients with IBD to maintain social isolation[12,13].

    As the world is gradually attempting to normalize, IBD physicians must face new challenges in terms of both future uncertainty, given the lack of supply of COVID-19 vaccines worldwide, and the ability to reorganize clinical activities for patients with IBD to provide optimal care while avoiding new outbreaks. Facing this scenario, this review aims to critically analyze the evidence on the effect of medications commonly used to treat IBD, as well as the management of the disease in its different degrees of activity, including the setting of SARS-CoV-2 infection.

    WHAT IS THE RISK OF SARS-CoV-2 INFECTION IN THE IBD POPULATION?

    Data on the incidence of SARS-CoV-2 infection among patients with IBD have been conflicting. Initial evidence suggested that patients with IBD had a lower risk of COVID-19 compared to the general population, as subsequent studies reported that no case of COVID-19 was diagnosed among patients with IBD followed in referral centers in China and Italy[14,15]. However, other studies assessing the risk of COVID-19 among patients with IBD reported incidence rates of 4.9 cases per 1000 patients with IBD in a Spanish cohort[16]and 2.5 cases per 1000 patients with IBD in France and Italy cohorts[17]. In a recent systematic review and meta-analysis by Aziz et al[7]comprising six studies that incorporated data from 9177 patients with IBD, the pooled incidence of COVID-19 in the IBD population was approximately 0.3%, which is greatly reassuring, as the incidence is on the lower side compared with the general population (0.2%-4.0%)[7]. Although there is limited evidence available, it seems that patients with IBD are not at greater risk of acquiring COVID-19, and SARS-CoV-2 infection does not seem to be more prevalent in patients with IBD than in the general population. However, this data must be interpreted with caution given that IBD patients might have better adherence to protection, social distancing and hygiene measures, which could explain the lower incidence in this population.

    MANAGING IBD MEDICATIONS DURING THE COVID-19 PANDEMIC

    Managing IBD medications during SARS-CoV-2 infection and COVID-19

    Managing IBD during the COVID-19 pandemic has been a challenge faced by clinicians and their patients, especially concerning whether to carry on with biologics and immunosuppressive agents in the background of a global outbreak of a highly SARS-CoV-2. The knowledge about the impact of this virus on patients with IBD, although it is still scarce, is rapidly evolving[18].

    In particular, concerns surrounding medications’ impact for IBD on the risk of acquiring SARS-CoV-2 infection or developing COVID-19, and potentially exacerbate viral replication and the COVID-19 course, are a current thinking of both practicing clinicians and providers caring for patients with IBD. Confounding a systematic management strategy reveals that evidence-based data are scarce[19].

    Providers caring for patients with IBD during the COVID-19 outbreak are opportune to reduce the burden of COVID-19 by assuming or sharing responsibility for multidisciplinary management of patients with IBD in this common clinical difficulty. The main goal that must be kept in mind is to treat active disease and maintain remission[20].

    Fortunately, the worldwide management of patients with IBD during the COVID-19 pandemic presents considerable agreement. Indeed, gastroenterologists, both adult and pediatric, and colorectal surgeons were attending the practical recommendations/ guidance and consensus statements from several societies of gastroenterology, endoscopy, surgery, and from the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) with adaptations based on local regional characteristics[18]. For instance, an international survey on this issue showed that most gastroenterologists reduced clinic visits, restricted steroid use, and postponed elective endoscopic procedures and surgery. Also, if a patient was diagnosed with COVID-19, biologics and immunomodulators were mostly held[21].

    Understanding the short- and long-term safety of drugs used in patients with IBD remains an important area of research, especially now in the middle of the COVID-19 pandemic. Preliminary evidence specified that except high-dose systemic steroids, using aminosalicylates, budesonide, antibiotics, rectal therapies, nutritional therapy, immunomodulators, and biologics, including anti-tumor necrosis factor (TNF) agents, anti-integrin, or anti-interleukin (IL)-12/23, were well tolerated without an increased risk of unfavorable evolution or duration of viral disease in patients with IBD that develop infection by SARS-CoV-2 and COVID-19[8]. However, recent accumulating evidence from SECURE-IBD registry based on data on over 1400 patients with IBD suggests that compared with anti-TNF monotherapy, thiopurine monotherapy, combotherapy of thiopurines with anti-TNF agent, and, surprisingly, aminosalicylates were associated with significantly increased risk of severe COVID-19, although the association with latter will require further replication in other IBD populations[22]. The authors of this study hypothesized that the influence of combotherapy on increased COVID-19 severity appears to be guided by thiopurines, as the estimated impact for thiopurines monotherapy and combotherapy compared with anti-TNF monotherapy were similar[22]. Furthermore, this hypothesis followed previous observations that found a higher risk of viral infections in patients during treatment with thiopurines alone or in combotherapy with anti-TNF agents[4]. In line with the British Society of Gastroenterology (BSG) statements[13], these researchers proposed the withdrawal of thiopurine while the ongoing COVID-19 pandemic in high-risk patients with IBD, for instance, those with older age or multiple comorbidities that are in stable remission on combotherapy with anti-TNF agent[22]. Also, in this international registry in progress, there are no significant differences between biological classes (anti-TNF, anti-IL12/23, and integrin antagonists) on the risk of developing severe COVID-19.

    Interestingly, some anecdotal reports have shown improvement in pulmonary symptoms and multisystem inflammatory syndrome related to COVID-19 in patients with active IBD treated with infliximab[23,24]. However, whether anti-TNF alpha therapy or other anti-inflammatory agents may protect against cytokine release syndrome in patients with COVID-19 will require further investigation[25]. Moreover, as advances in IBD therapy broaden the therapeutic arsenal, it will be necessary to maintain investigations using collaborative multi-center registries for evaluating the possible impact of novel agents, such as Janus kinase inhibitors, IL-23 antagonists, and others, on SARS-CoV-2 or COVID-19. It should be highlighted that as the knowledge regarding SARS-CoV-2 progresses, it is likely that IBD-specific recommendations in the COVID-19 setting also undergo substantial changes[26].

    Managing patients with IBD infected with SARS-CoV-2 depends on both the clinical activity of the IBD and the occasional development and severity of COVID-19[12,27]. For practical purposes, we will present current recommendations for managing drugs for IBD concerning the SARS-CoV-2 infectious status into distinct clinical scenarios: (1) The patient attending outpatient clinic with IBD in remission in the setting of the asymptomatic SARS-CoV-2 infection or confirmed or suspected COVID-19; (2) The patient with active IBD undergoing outpatient follow-up in the setting of the asymptomatic SARS-CoV-2 infection or confirmed or suspected COVID-19; and (3) The patient with IBD hospitalized with asymptomatic SARS-CoV-2 infection or COVID-19.

    Management of patient attending outpatient clinic with IBD in remission in the setting of asymptomatic SARS-CoV-2 infection or confirmed or suspected COVID-19 without systemic hyperinflammation syndrome

    As the COVID-19 pandemic expands, an increasing number of tests for SARS-CoV-2 are being conducted, including asymptomatic contacts of COVID-19 index cases. Thus, the situation in which an individual tests positive for the virus but remains asymptomatic will be more and more frequent.

    The IOIBD recommends for quiescent patients with IBD with asymptomatic SARSCoV-2 infection — quick withdrawal of prednisone or de-escalating to < 20 mg/d or switch to budesonide or budesonide MMX (Multi Matrix System) when appropriate[12]. Immunomodulators such as thiopurines, methotrexate, and tofacitinib (or other Janus kinase inhibitors) should be temporarily held for 2 wk while monitoring for the appearance of COVID-19 symptoms[12]. Similarly, biologic administration, including anti-TNF drugs, vedolizumab, and ustekinumab, should be postponed for 2 wk if the dose is due, even recognizing that the half-lives of these biologics are relatively long, so that immunosuppressive effects of these drugs will persist for a few additional weeks despite the withdrawal of these agents[26]. Conversely, nonimmune-based anti-inflammatory therapies such as aminosalicylates, antibiotics, budesonide, or rectal therapy may be continued[22,26]. However, for patients with IBD who have had the closest contact with an individual with proven or suspected COVID-19, it is suggested that they isolate themselves and follow local recommendations from health managers. In this situation, European Crohn and Colitis Organization (ECCO) experts recommend that it is unnecessary to hold biologics or immunomodulators based on exposure only[20].

    For patient attending outpatient clinic with quiescent IBD but with confirmed or suspected COVID-19, the approach to drug management is like that adopted for patients with asymptomatic infection by SARS-CoV-2. The American Gastroenterology Association (AGA) and IOIBD experts suggest that budesonide, aminosalycilates, antibiotics, and topical therapy may be maintained while systemic corticosteroids (prednisone) should be avoided and withdraw speedily, if possible. Likewise, it is recommended to hold immunomodulators, Janus kinase inhibitors, and biologics until after disappearance of symptoms, usually for 2 wk during the acute disease[12,26].

    Management of patient with active IBD undergoing outpatient follow-up in the setting of asymptomatic SARS-CoV-2 infection or confirmed or suspected COVID-19 without systemic hyperinflammation syndrome

    Currently, in the COVID-19 era, if a patient with IBD presents an apparent flare, it is important to always question the presence of concomitant symptoms suggestive of COVID-19, such as fever, cough, anosmia, or dyspnea, because GI symptoms including diarrhea, nausea, vomiting, and abdominal pain have been reported in 2%-33% of patients on initial presentation of COVID-19[28]. Moreover, in a few cases, these digestive symptoms may be the only clinical features of COVID-19[29]. This context is a clinical challenge, compounded by the frequent finding of remarkably elevated serum inflammatory biomarkers in patients with COVID-19.

    When a patient with IBD presents diarrhea, it is doubtful whether this is secondary to a disease flare or COVID-19, a wait-and-see approach for the next 5-7 d is a reasonable strategy[27], once the diarrhea due to COVID-19 is mostly mild and selflimited, usually with an average duration of 5 d (range, 1 d to 14 d ) and a mean frequency of four bowel movements per day[30]. Also, follow-up using interval assessment of fecal calprotectin (FC) may be useful, as FC levels are typically both transiently raised and mildly elevated in patients with diarrhea caused by COVID-19[31]. In contrast, in active IBD, sustained and substantial elevation of FC is commonly seen. In any case, in the current era of COVID-19, the joint expert consensus from ECCO recommends that all patients with a suspected IBD flare be tested to exclude COVID-19 preferably with oropharyngeal and nasopharyngeal swabs reverse transcription polymerase chain reaction (RT-PCR) assays when the first symptoms emerge[20].

    In cases where, after initial assessment, diagnostic doubts remain, computed tomography (CT) scans of the chest, abdominal cross-sectional imaging methods, and, more restrictively, ileocolonoscopy assessment can allow the real cause of diarrhea to be established[20]. Another question that remains unknown is whether SARS-CoV-2 can cause a flare of or de novo IBD[19]. Moreover, in patients with apparently active IBD (especially colonic IBD), it is important to be aware to exclude enteric superinfections, mainly due to Clostridioides difficile (C. difficile) and cytomegalovirus (CMV), assess adherence to therapy, and perform therapeutic drug monitoring of biologics[27].

    If GI symptoms (including diarrhea) are not caused by COVID-19 and other causes for IBD flare are excluded, such as enteric superinfection, nonsteroidal antiinflammatory use, and non-adherence to therapy, the drug management for IBD will depend on the equilibrium between the severities of the IBD flare and those of the COVID-19[18-20]. For a flare of mild severity in outpatients with asymptomatic infection by SARS-CoV-2 or with mild to moderate COVID-19 without systemic hyperinflammation syndrome (SHS), it is recommended tapering off prednisone or its equivalent for < 20 mg/d with complete weaning where possible, balancing with the potential for possible adrenal insufficiency in the setting of chronic corticosteroid therapy[12,26,27]. Another option that can be considered in patients using systemic steroids is converting to oral budesonide or budesonide MMX on adequate dosing, provided the patient is in the appropriate clinical setting (e.g., mildly to moderately active ileocecal CD or UC, respectively). Further, it is suggested stopping or avoiding commencing immunomodulators, tofacitinib (or other Janus kinase inhibitors), and biologics for at least 2 wk during viral illness, while budesonide, aminosalycilates, antibiotics, and topical therapy may be initiated or maintained if needed[26,27].

    The approach for a IBD flare-up moderate to severe in patients attending outpatient clinic with COVID-19 without SHS may include continuation of current biological therapy for IBD with optimization to rescue a state of remission or starting a new biological agent if needed, preferably in monotherapy and with subcutaneous biologics to reduce the risk of exposure to SARS-CoV-2 in infusion units[20,27].

    In this clinical context, if glucocorticosteroids are considered essential, the dose of prednisone (or its equivalent) should be ≤ 40 mg/d limiting the duration of use, if practicable[26]. Also, it is advised to stop if in use or avoid commencing immunomodulators or tofacitinib. If COVID-19 is progressive with significant pulmonary involvement and hospitalization, consultation with infectious diseases experts for possible COVID-19 treatment with antiviral or experimental anticytokine therapy may be interesting[19,20,27]. In Tables 1-3, we present an approach for managing IBD medications in patients attending outpatient clinic who are infected with SARS-CoV-2 with or without COVID-19.

    Table 1 Management of patients attending outpatient clinic with quiescent inflammatory bowel disease in the scenario of asymptomatic severe acute respiratory syndrome coronavirus 2 infection or confirmed or suspected coronavirus disease 2019[12,20,26,27]

    Table 2 Management of patients attending outpatient clinic with mildly active inflammatory bowel disease in the scenario of the asymptomatic severe acute respiratory syndrome coronavirus 2 infection or confirmed or suspected coronavirus disease 2019[12,20,26,27]

    Table 3 Management of patients attending outpatient clinic with moderately to severely active inflammatory bowel disease in the scenario of asymptomatic severe acute respiratory syndrome coronavirus 2 infection or confirmed or suspected coronavirus disease 2019[12,20,26,27]

    Management of patients with IBD hospitalized with asymptomatic SARS-CoV-2 infection or COVID-19

    Although the ongoing COVID-19 pandemic has substantially impacted the management of IBD, with unprecedented restriction of hospitalizations, many patients with IBD will still be hospitalized in the COVID-19 era either because of severely active or complicated IBD, or because they were infected with SARS-CoV-2 and developed progressive or severe COVID-19 with SHS requiring supplemental oxygen or ventilator support, use of vasopressors, or present evidence of end organ damage[19,26]. In fact, hospitalization should be restricted to life-threatening circumstances or complications[20].

    For patients hospitalized with severe COVID-19, the priority is life support, while IBD therapy is likely to have less priority. Nonetheless, when possible, therapy for COVID-19 should consider the underlying IBD[12,27]. Ideally, treatment decisions should be personalized and decision-making should include a multidisciplinary approach, involving teams of experts on both conditions. This way, consultation with pulmonary medicine and infectious disease experts is crucial, with discussion involving the possibilities of COVID-19 treatment with experimental antiviral drugs or anticytokine therapy trials, and staying aware of potential interaction with IBD medications[32]. If IBD is mildly active, budesonide, aminosalycilates, and rectal therapies may be initiated while reducing or holding prednisone. Also, stopping biologics, immunomodulators, and tofacitinib throughout the duration of the COVID-19 is appropriate[18,19,26]. For moderately-to-severely active IBD, the limited use of intravenous corticosteroids for IBD is acceptable, if necessary. Topical therapy may be ordered if deemed adequate, while immunomodulators, tofacitinib, or biologics that failed for IBD should be stopped[18,19,27]. Other therapies for IBD should only be used if definitely required. Intravenous cyclosporine may be a reasonable option for severe UC, based on limited evidence of its benefit against coronavirus[26,27].

    Interestingly, in a recent trial involving patients without IBD hospitalized with COVID-19, patients were randomized to therapy with oral or intravenous dexamethasone at a dose of 6 mg once daily for up to 10 d or until discharge, whichever was sooner, or to receive usual care only[33]. The group treated with dexamethasone presented significantly lower 28-d mortality in patients receiving either oxygen alone or with invasive mechanical ventilation (23.3% and 29.3% vs 26.2% and 41.4% with usual care, respectively). Importantly, the same benefit was not found in subjects receiving no respiratory support[33]. Whether other glucocorticoids like methylprednisolone or hydrocortisone on equivalent doses might also be effective in this setting is unknown and will require future studies. From the perspective of pharmacological effects and on the immune system, there is nothing specific about dexamethasone that other steroids do not offer as well, and so other glucocorticosteroids could in theory be used if dexamethasone is unavailable[34]. If this hypothesis is confirmed in prospective studies, this important therapeutic strategy can help us clarify our approach for suitably managing the challenging and lifethreatening scenario of a patient hospitalized that concomitantly presents with a severe flare of IBD and moderate-to-severe COVID-19, where intravenous methylprednisolone or hydrocortisone could be one of the first-line therapies for both conditions.

    However, for patients hospitalized due to severe flare of UC and who also have asymptomatic infection with SARS-CoV-2 or mild-moderate COVID-19, priority must be given to address issues pertinent to severe exacerbation of IBD, and usually a standard approach directed to the care of hospitalized patients with IBD should be followed[26,35]. In this clinical setting, expert opinions of the AGA recommend limiting intravenous steroids to three days and then transitioning to infliximab or cyclosporine[20]. Evaluating enteric superinfections, especially those caused by C. difficile or CMV, using fecal toxin A/B enzyme immunoassay and/or PCR for detecting toxins A and B genes or for detecting CMV DNA by quantitative PCR should be a routine practice for these patients[27]. In contrast, when CMV superinfection remains suspected despite the results of non-invasive tests, urgent colonoscopy should be reserved for patients in whom the procedure may change or target a specific therapy[12,19,20]; also, colorectal surgery expert consultation in the first days of hospitalization of the patient should also be a standard practice in this context[35]. Foremost, a recent ‘RAND appropriateness panel’ adapted from the BSG guidelines for managing acute severe UC recommended that regarding the COVID-19 pandemic, prophylactic anticoagulation post-discharge is ordered for patients hospitalized with acute severe colitis that had a positive SARS-CoV-2 testing due to the predisposition to develop thromboembolic complications in both conditions[36]. Indeed, the British Thoracic Society proposes that it is a reasonable approach to consider extended venous thromboembolism prophylaxis on discharge with low molecular weight heparin or direct oral anticoagulant during four weeks in high-risk patients with COVID-19[37]. Table 4 depicts the suggested approach for managing patients with IBD hospitalized with severe COVID-19.

    When to restart biological and other immunosuppressive agents in patients with IBD infected with SARS-CoV-2 with or without COVID-19

    Considering that patient safety should be a priority in the context of still limited but rapidly expanding knowledge regarding the management of IBD during the COVID-19 pandemic, most consensus statements and expert opinions recommend temporarily holding biologics and other immunosuppressant drugs in patients with IBD with asymptomatic SARS-CoV-2 infection or in the presence of symptoms suggestive of COVID-19 until a patient recovers[38]. However, if used prolongedly, this practice can lead some patients to both lose the effectiveness of their therapy and present an IBD flare[39]. Therefore, guidance on when to restart IBD medications in this setting is very welcome.

    Table 4 Management of patient with inflammatory bowel disease hospitalized with severe coronavirus disease 2019[12,19,20,26,27]

    Although the timing for treatment restart is nonconsensual, currently, for decision making, the IOIBD expert panel recommends preferably for most patients a symptoms-based strategy due to the lack of accuracy of current molecular tests available for diagnosing SARS-CoV-2 infection, and also because of the clinical significance still unclear of the prolonged persistence of viral RNA detected by these tests in individuals that had COVID-19[38].

    In asymptomatic patients with SARS-CoV-2 infection, some experts advise waiting at least 10 d from the first positive COVID-19 test for restarting immunosuppressive drugs as long as there is no development of symptoms suggestive of COVID-19 in this time interval[12,38]. In patients with COVID-19, the timing of resumed biologics or other immunosuppressants should be guided by the balance between the severity of both viral disease and IBD[38]. Thus, based on updated guidelines from the IOIBD, using a symptom-based strategy, it is recommended to wait at least 10 d since the appearance of the first symptoms of COVID and at least 3 d since recovery, defined as resolution of fever and significant improvement in respiratory symptoms, to re-start these medications[38]. Having two consecutive negative PCR tests in swab specimens, collected at least 24 h apart, is no longer required when this strategy is embraced[38,40]. In severe COVID-19, a longer time frame for re-initiating immunosuppressant may be necessary according to the personalized clinical strategy, if possible awaiting full patient recovery[41]. However, when doctors require a test-based strategy to decide about restarting IBD medications, in addition to the patient having clinically recovered based on the described parameters of the symptom-based strategy, he must have two consecutive negative nasopharyngeal swabs COVID-19 molecular assays collected at least 24 h apart[38].

    MONITORING IBD TREATMENT DURING THE PANDEMIC

    The outbreak of the COVID-19 infection forced government authorities to impose several restrictions, including lockdown[42]. Hospitals were then forced to rapidly restructure their activities to accommodate this critical and emergent situation. Institutional rearrangements have challenged IBD units worldwide, forcing them to adapt and generate specific approaches to maintain appropriate IBD care[10]. Referral IBD centers and Gastroenterology/IBD Societies published their guidance, helping clinicians tackle this troublesome situation[10,12,13,19,26,42-47]. In common, they advised remote monitoring, drug home delivery whenever possible, infusion unit restrictions, and patient education concerning protective measures (Table 5). Although necessary, all these measures and restrictions may negatively impact patients with IBD. A recent survey among 225 patients with IBD from a referral center showed depressive moodas the most prevalent social impact (80.2%), followed by anxiety/fear of death (58.2%), insomnia (51.4%), daily activity impairment (48%), sexual dysfunction (46.2%), and productivity impairment (40%)[11]. These health repercussions in patients with IBD are essential, and healthcare professionals should be aware of them when talking remotely with the patients.

    Table 5 Approach to diminish the spread of coronavirus disease 2019 for patients with inflammatory bowel disease[10]

    A common feature in the various IBD units is that telemedicine has replaced followup visits[48]. Although not the ideal way to follow these patients, that was the best way to do it now. Some authors prefer to term these remote visits video office or telephone office visits[44]. They avoid the term “virtual,” which could mistakenly connote that the visits were not “real”[44]. In general, patients found those remote visits worthwhile, but no doubt, this was exhausting for the healthcare professionals that ended up with the well-described “zoom-fatigue”[44]; consequently, the personal visits were reduced by 30%-40%[10,42-44]; for comparison, endoscopic procedures were reduced by 90%-95%[10,42-44]and were indicated in selected cases[42,44,49,50]. Image procedures were also largely deferred and only indicated in cases of intestinal obstruction or suspected abscess[44]. There has been a lack of information on the impact of remote monitoring of patients with IBD during the SARS-CoV-2 pandemic. In a single-center cross-sectional Italian study with 1083 patients with IBD, telemonitoring of patients by phone or videoconference was compared with clinical evaluation in person (control group)[48]. Despite fewer relapses in the control group, there were no statistically significant differences between the groups regarding the quality of life measured by the IBDQ-32 questionnaire[48]. Thus, the possibility of contacting the IBD staff through remote monitoring, although not ideal, partially contributes to maintaining the quality-of-life parameter.

    FC has been a valuable tool during this pandemic[27]. Many centers have relied on commercial labs to send an overnight home stool collection kit for FC that can be picked up by express mail services, avoiding the patient from leaving home[44]. A home FC test (IBDoc) was compared with a laboratory test (Quantum Blue?calprotectin test, BüHLMANN, Sch?nenbuch, Switzerland) and the correlation between both tests was good (r = 0.776, P < 0.0001)[51]. Using 250 μg/g as the cutoff, the agreement between the home and laboratory tests was 80%[51]. Diarrhea can be one of the manifestations of COVID-19 or an IBD flare[27]. FC can be particularly useful to differentiate these situations since FC is usually only mildly elevated in patients with COVID-19 with diarrhea, whereas in patients with IBD and active disease, significant and sustained elevation may occur[27].

    ENDOSCOPY IN PATIENTS WITH IBD IN THE COVID-19 ERA

    Endoscopy is not only one fundamental pillar for diagnosing IBD but also plays an important role in its management, treatment, and colorectal cancer (CRC)/dysplasia surveillance. Differential diagnosis concerning other etiologies and between UC and CD as well as full evaluation of disease extension, activity, response to treatment, and even some therapeutic approaches are some endoscopic indications in a patient with IBD. Ileocolonoscopy, flexible proctosigmoidoscopy, and esophagogastroduodenoscopy are the most commonly used endoscopic methods, but enteroscopy and videocapsule endoscopy also play a role in IBD management[52,53]. The overcrowded healthcare system worldwide by the COVID-19 pandemic and the need to control the spread of infection required restructuring primary care and hospital activities, including endoscopy units[43,54].

    Risk of infection during endoscopy

    Regardless of being more contagious than the other coronavirus (SARS-CoV and Middle East respiratory syndrome coronavirus), SARS-CoV-2 has similar ways of infection and complications[55], with aerosolized droplets produced by coughing, sneezing, or breathing as the main route of infection. SARS-CoV-2 infects the GI epithelium, and its RNA can be detected in stool samples, sometimes in high concentrations, even in patients without GI symptoms, lightening the possibility of fecal–oral transmission[55]. Although this route of transmission is controversial, some papers proved the presence of live virus in fecal specimens and even a positive PCR in material collected from the surface of the toilet and sink used by infected patients, thereby corroborating this route of transmission[56].

    Both upper and lower GI endoscopies should be considered as aerosol-generating procedures. Upper GI endoscopy can generate respiratory droplets by coughing or gagging induced mainly during endoscopic insertion and lower GI endoscopy by passing flatus or pathogen-containing stools[57]. Therefore, endoscopy can be considered a high-risk procedure for SARS-COV-2 transmission for both patients and healthcare professionals, being reasonable to ration the endoscopic resources.

    Indications of endoscopy during COVID-19 pandemic

    To minimize the exposure and risk of infection, different Societies of Gastroenterology and Endoscopy worldwide (American Gastroenterological Association[58], BSG[13], European Society of Gastrointestinal Endoscopy and European Society of Gastroenterology and Endoscopy Nurses and Associates[59], Asian Pacific Society for Digestive Endoscopy[60], and Brazilian Society of Digestive Endoscopy[61]) agreed to postpone all the endoscopic procedures during the pandemic period, except for the emergency ones and on a case-by-case basis, some urgent ones. The emergency and urgent endoscopic procedures can be resumed and divided into the following three categories: Emergent, urgent, and elective (Table 6)[62]. The restriction in the indications for GI endoscopy aimed not only to reduce the risk of patients and healthcare professional infection but also to save personal protective equipment (PPE) and other medical supplies[57].

    Endoscopy, especially ileocolonoscopy, plays a fundamental role in the diagnosis and management of IBD, ruling out some other diagnoses and providing important information about the extension and activity of the disease, response to treatment, and even a therapeutic approach to stenosis and other complications. During the COVID-19 pandemic, these indications for patients with IBD were reviewed and based on expert opinions, the IOIBD[63]and French Society of Digestive Endoscopy (SFED) recommendations[64], the advice was again to postpone all endoscopic procedures that were not urgent and extremely necessary. However, sometimes, this emergent/urgent indication for endoscopy in patients with IBD is slightly unclear. Thus, next we are going to discuss some possible scenarios[57]:

    Confirm IBD diagnosis:In highly suspected cases with moderate-to-severe symptoms and grounded by positive biomarkers and cross-sectional imaging findings (bowel ultrasonography or magnetic resonance enterography) of IBD, lower GI endoscopy (proctosigmoidoscopy or colonoscopy) with biopsies is still indicated[57]. Depending on the clinical situation and the presence of rectal symptoms, proctosigmoidoscopy might be preferable to full colonoscopy, as the former is faster and can be done without sedation (no need for companion) or oral bowel preparation[63]. Cases with mild symptoms can have their endoscopy postponed[57,63,64]. If an isolated small bowel disease is the hypothesis, after negative cross-sectional imaging and in the absence of obstructive symptoms, videocapsule endoscopy should be preferred to enteroscopy for its lower risk[64].

    Monitoring IBD treatment:Disease activity monitoring, if possible as mentioned before, should be made by checking patient report outcomes (PROs) and noninvasive tests such as FC, C-reactive protein (CRP), or even cross-sectional imaging[64,65].

    Acute severe UC:This is an emergency condition with a high morbimortality. A patient who fulfills the criteria of a stool frequency (≥ 6 per day), with bloody stools, heart rate above 90 bpm, temperature exceeding 37.8 °C, hemoglobin levels below 105g/L, and high CRP levels (> 30 mg/L) needs to be hospitalized and undergo investigation to rule out infections other than IBD activity, especially COVID-19, C. difficile, and CMV[66,67]. Symptoms such as fever, cough, dysosmia, dysgeusia, and fatigue need to be questioned, and a PCR for SARS-COV-2 asked. If negative, analysis of stool samples should be performed looking for C. difficile and parasitological infection and, in this setting, it is advised to perform flexible proctosigmoidoscopy with biopsies to exclude CMV infection[57,63,64].

    Table 6 Category of endoscopic procedures[13,62]

    Postoperative recurrence assessment:Endoscopy plays an important role in the postoperative management of both CD and UC patients. In CD, mainly in cases of ileocecal resection, since endoscopic inflammation precedes biological and clinical activity, ileocolonoscopic findings allow us to tailor therapy. In UC patients, postoperative endoscopy is mainly indicated for pouchitis and surveillance of this segment for dysplasia. However, when we consider the risks and benefits of the procedure during this pandemic period, endoscopy to check postoperative recurrence and dysplasia could be delayed, and for inflammation, patients should be followed noninvasively[63,64,68].

    Surveillance colonoscopies:It is known that patients with IBD have twice more risk of CRC than the general population, justifying the importance of its screening and surveillance. Based on ECCO guidelines, surveillance colonoscopy is indicated for all patients with UC, except if the disease is restricted to the rectum eight years after the beginning of the symptoms. Patients with colonic CD with more than 1/3 of the colon affected should follow the same protocol. If primary sclerosing cholangitis (PSC) is present, surveillance is recommended to start immediately when the diagnosis is confirmed and continues yearly. The interval between colonoscopies will depend on the risk factors and the results obtained in the index exam[66]. However, for all the risks listed above, the recommendation is to postpone the colonoscopy in patients without alarming signs. With the extension of the pandemic period, this recommendation needs to be reviewed, and probably the patients will be stratified by risk factors for CRC, as with PSC or previous dysplastic lesions, and will be rescheduled as priorities for endoscopic examination[57,64].

    Partial GI obstruction:Patients with IBD are at higher risk of some complications, such as benign or malignant strictures. In cases of a new colonic stricture, a colonoscopy is indicated to exclude malignancy, and if this hypothesis is confirmed, a stent or balloon dilatation might be needed if surgery could not be performed. In CD patients with a known short stricture (< 4 cm) with recurrent obstructive symptoms (nausea, vomiting, weight loss, and abdominal pain), endoscopic dilatation is a therapeutic option to avoid future admission to the emergency room, overloaded during COVID-19 pandemic[57,68].

    Upper GI endoscopy:The indications for upper GI endoscopy in patients with IBD during this pandemic period are restricted to acute GI bleeding or dilatation of upper GI strictures[64].

    Worsening cholangitis and jaundice in patients with IBD and PSC with a dominant bile duct stricture:Acute cholangitis in a patient with PSC is an emergency, and if there is a dominant bile duct stricture detected on a magnetic resonance cholangiography, an urgent endoscopic retrograde cholangiopancreatography (ERCP) will access the stricture to exclude cholangiocarcinoma and may decompress the bile duct[57].

    Endoscopy in industry-sponsored clinical trials:Most of the recruitment of new patients and screening visits for clinical trials have been discontinued during this pandemic period, but the status of monitoring colonoscopies for participants already recruited should be discussed with trial sponsors and research ethics committees. A case-by-case discussion might be necessary, as for some patients, the investigational product is the only therapeutic option to avoid surgery and/or corticosteroids. Trial visits should occur virtually whenever possible[57,64].

    In summary, endoscopy in patients with IBD during the COVID-19 pandemic should be restricted for the indications listed in Table 7.

    Safety measures for protection against COVID-19 infection

    Aiming to mitigate the risk of the spread of infection from possible COVID-19 patients, reduce the risk of cross-infection, and preserve resources and PPE, some measures are recommended by different GI endoscopy societies[62,69]. The safety recommendations can be targeted to the unit structure, patient safety, healthcare professional safety, and equipment/endoscopy room care.

    Unit structure[57,70]:Limit the number of patients scheduled; Consider at least a onehour interval between exams; Select the indications of endoscopy and postpone the others; Remote pre-exam evaluation with a questionnaire about COVID-19 symptoms and contact; Inform the need to wear a mask; Apply social distancing rules in the waiting room; Avoid physical contact; Limit the waiting room time and number of people; Reassure that just exams with sedation or anesthesia require a companion; Relatives and caregivers are forbidden from entering the hospital or endoscopy unit unless required; Medical and nursing students are restricted in the endoscopy units during pandemic crises; Allow only essential staff with proper PPE inside the endoscopic unit; Keep doors closed; Provide information about hand hygiene; Followup call one week after endoscopy: As symptoms of COVID-19 can occur after infection, patients undergoing endoscopy could develop symptoms after the procedure if they have contracted the SARS-CoV-2 infection at the community level just before endoscopy. It is a way to verify whether the protective measures at the unit are working[64].

    Patient safety[64]:Check again for COVID-19 symptoms (fever > 37.5 °C; cough, dysgeusia, dysosmia, and dyspnea) or contact at admission; Access body temperature; Provide the patient alcoholic solution to clean hands; Before entering the endoscopy room, the patient is asked to dress a cotton gown, a hairnet, and a surgical mask; Nasal swabs are not a routine recommendation, as they are not generally available or validated.

    Healthcare professionals’ safety[64,70,71]:AGA and the SFED recommend the use of filtering face piece (FFP) respiratory class 2 or 3 (FFP2 or FFP3) instead of surgical masks to protect Healthcare professionals (HCPs) during upper and lower GI procedures, regardless of the COVID-19 status of the patient. The suggestion for mask changing depends on regional recommendations; Limit the number of endoscopy personnel and operational endoscopy rooms; Endoscopy work teams should comprise a consultant endoscopist, a highly trained endoscopy nurse, and, if possible, a consultant anesthesiologist; HCPs should be checked for COVID-19 symptoms and having their body temperature accessed; HCPs should wear FFP2 mask during the entire time at endoscopy unit as SARS-CoV-2 remained viable in aerosols for at least 3 h; HCPs should be trained in dressing and undressing the PPE, and hand washing is mandatory before both phases; HCPs must remove contact lenses and dress: Hairnet, a long water-resistant gown with back closure, an FFP2 mask, goggles for eye protection, and over-sleeve gloves over the gown. Over the other layers, a single-use gown and another pair of gloves; HCPs should change the disposable gown and the second gloves in each procedure; Hand washing is mandatory before and after every interaction with patient and other HCPs; Conscious sedation remains the most feasible option and can be provided and managed even if the patient is wearing a mask.

    Equipment/endoscopy room[62,64,72]:Negative-pressure room to prevent generated aerosols from diffusing outside the room is recommended mainly in COVID-19 confirmed or highly suspected cases; Disinfection and decontamination by neutral detergent and virucidal disinfectant using 0.05% sodium hypochlorite or 70% ethanol on surfaces and devices are effective in clearing the virus; All used endoscopes must undergo standardized reprocessing and disinfection; All used accessories must be disposed of; Beds must be cleaned with specific disinfection products and bed sheets changed for each patient.

    Table 7 Indications for gastrointestinal endoscopy in patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic[57,63,64]

    Endoscopy post-pandemic phase

    When the COVID-19 pandemic ends, endoscopy units must face a dammed demand list with the impossibility of returning to a regular agenda, as the interval between the exams will need to remain longer to prevent new outbreaks. A stratification of priorities will be necessary[73]. Some algorithms based on available point-of-care tests considering epidemiological regional data and an accurate clinical risk assessment are being proposed to stratify the patients[74]. Whatever method is used to prioritize endoscopy, it is important to maintain close contact with patients with IBD by phone or e-mail to monitor for specific symptoms. Planning carefully the post-pandemic phase is primordial, and a case-by-case analysis with reassessments of patients’ conditions by both clinician and endoscopist will be demanded, and telemedicine might be a useful tool to help this conversation[73].

    SURGICAL INTERVENTIONS IN PATIENTS WITH IBD AND COVID-19

    Despite significant advances in the medical management of IBD in recent years, many patients will require surgery. The most common indications for CD surgery include stenosis, fistulae, and abscesses[75]. In UC, the most common indications are acute severe colitis refractory to medical therapy and chronic refractory UC. Other indications of surgery in UC are dysplasia and CRC[76]. Many of these situations are elective or semi-elective surgeries that can be postponed for a few days or weeks in some patients with confirmed COVID-19. However, emergencies, such as perforation, acute severe colitis, and uncontrolled hemorrhage, may occur, and the surgery in these cases cannot be postponed and must be treated promptly. At the peak of the pandemic, one of the collateral effects was that elective surgeries were canceled or temporarily suspended[77]. Elective surgeries in IBD cannot be delayed too long when they are strictly indicated, mainly due to increased morbidity given the patient’s weakened condition (e.g., steroids and malnutrition)[78]. It is not recommended to delay surgical treatment for these patients with IBD, regardless of their COVID-19 status.

    Conducting emergency surgeries during a pandemic such as COVID-19 is challenging for IBD surgeons and the entire hospital infrastructure[79,80]. The information available on COVID-19 and the possibility of contamination through aerosols and droplets lead to the need for modifications to perform surgery with success, reducing the risk of contaminating hospital facilities and protecting health teams and patients[79]. It is pivotal to protect all surgical teams (e.g., masks, glasses, face shields, and surgical caps) to avoid contagion with COVID-19 when they perform surgery in patients with IBD with suspected or confirmed COVID-19 and protect the patient to prevent him from contracting COVID-19.

    There is a concern among surgeons with minimally invasive techniques (e.g., laparoscopy, and robotic surgery) due to a possible risk of viral transmission of the COVID-19 with the creation of pneumoperitoneum[81]. However, minimally invasive surgery (MIS), including laparoscopic surgery, is feasible and safe in IBD and has many advantages, such as reduced length of hospital stay, less pain, reduced trauma, less impact on respiratory movements, reduction of morbidity, and faster postoperative recovery[82].

    There is little evidence of viral transmission through laparoscopic or open approaches. As shown by Somashekhar et al[79], the risk of infection by COVID-19 for the healthcare team during MIS (laparoscopic or robotic) is considered low. Therefore, in IBD, we should not postpone surgery, even if considered “elective,” due to the COVID-19 pandemic. Thus, the care that must be followed by the surgical, nursing, and anesthesia teams must be standardized at the referred hospital and replicated to other health services referenced in the surgical treatment of IBD.

    Precautions to avoid contamination of the surgical team are described in several studies published during the pandemic and include care with airway management during the anesthetic procedure and specific care during laparoscopy[79,81,83-85]. There seems to be a consensus in the literature that intubation and extubation are high-risk healthcare professionals’ procedures and that the maximum amount of PPE is needed. However, there is little evidence of the real risk of contamination by healthcare professionals during laparoscopy itself, nor of operating room (OR) pressure, surgical smoke, tissue extraction, or CO2deflation[83]. If surgery is considered necessary, the surgeon must minimize the risk of exposure to the virus, involving a minimum number of health professionals and shortening the occupation of the ORs. As said, there are no absolute contraindications to MIS; however, appropriate PPE for the OR team and smoke evacuation/filtration systems are unanimously recommended[85].

    If there is a lack of safety measures to allow safe laparoscopy, open surgery should be considered[84]. Nevertheless, previous studies have shown that bacterial and viral aerosols can be detected in both open and laparoscopic surgical operations[86]; then, a surgical aspirator/smoke evacuation device should also be used in open procedures. Electrical instruments and energy devices should be used at the lowest energy level to preclude excessive aerosol and smoke production[87].

    There are some tips and tricks to make MIS safer during the COVID-19 pandemic, such as avoid creating a leak for smoke evacuation, use a closed suction system; use leak-free trocars such as balloon trocars, aspirate the entire pneumoperitoneum before retrieving the surgical specimen at the end of a procedure before removing the trocars, or before conversion to open surgery[84]. Hospitals must prepare specific internal protocols and arrange adequate training of the involved personnel[88].

    If possible, postpone elective surgery and consider screening every surgical patient for COVID-19 either by RT-PCR swab or CT scan of the thorax[89]. In emergent (< 24 h) surgeries, such as perianal abscess, bowel perforation, toxic megacolon, the surgery must be done without any delay, and all patients must be treated as if they were COVID-19-positive. All surgical teams must strictly follow all rules related to infection against COVID-19. The same rules apply to patients under urgent (< 72 h) situations, such as bowel obstruction (without ischemia). Elective (up to 4 wk to 3 mo) surgeries must have an individualized approach. Seton replacements, “J” pouch confection, can be postponed up to three months. However, colectomy in patients with chronic refractory UC or dysplasia and CRC in UC should be referred to surgery, preferably before this period, so that there will be no worsening of the primary clinical condition.

    It is important to emphasize that all known or suspected COVID-19-positive patients requiring surgical intervention must be treated as positive until proven otherwise to minimize infection spread[88]. Besides, whenever possible, dedicate specific OR to patients with COVID-19[83]. Create negative pressure ORs because they are considered ideal; yet, most ORs work at positive pressure, and their use is therefore permitted. An air exchange rate of ≥ 25 cycles/h is considered sufficient to effectively reduce the OR’s viral load. Only essential staff members should be admitted into the OR, limiting in/out traffic, and doors should be kept closed. Use level III PPE during intubation and extubation. Use proper filters and closed systems for CO2desufflation and do not perform transanal surgery[83].

    There are some critical considerations for transanal surgery during the COVID-19 pandemic[90]. Several lines of evidence have supported the possible fecal-oral transmission of the COVID-19[91,92]. It is important to emphasize that positive pressure transanal surgery, such as transanal MIS and transanal endoscopic microsurgery, are aerosol-generating procedures. Hence, it is appropriate to perform routine preoperative fecal testing for SARS-CoV-2, in addition to nasopharyngeal screening, in patients undergoing transanal surgery under positive pressure. For patients with confirmed SARS-CoV-2 infection, conventional open and robotic approaches may be safer alternatives when surgery cannot be postponed.

    MENTAL HEALTH AND EDUCATIONAL INITIATIVES

    It has been recognized that the pandemic will greatly increase the incidence of severe psychological problems, such as mood disorders, anxiety disorders, or posttraumatic stress disorder (PTSD), as a consequence of isolation, human losses, and financial hardships[93]. For patients with IBD, psychological distress is already a common feature, with studies suggesting that active disease is strongly related to comorbid anxiety and depression[94]. A recent cross-sectional survey exploring the emotional state, perception, and concerns of Saudi patients with IBD during the pandemic found a diagnosis of anxiety in 48.4% of surveyed patients. In this context, patients with IBD require greater attention, and clinical or cognitive behavioral treatment should be offered to all patients who exhibit psychological distress.

    Provided that patients with IBD are experiencing substantial changes to the routine management of their conditions during the pandemic, it seems highly critical to assess patients’ perceptions and viewpoints. In the earlier phase of the pandemic, the Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) conducted an anonymous online survey to investigate the concerns, fears, and behaviors of patients with IBD. Based on responses from 3815 participants from 51 countries worldwide, it was shown that about half of respondents reported receiving COVID-19 information or specific recommendations from doctors to prevent infection. However, most patients (60%) would have preferred to receive more recommendations regarding COVID-19 from their physicians[95]. These results emphasized the urgent need for better communication between physicians and patients and for clear and specific recommendations for people with chronic conditions in these unprecedented times. In this context, educational initiatives involving patient associations might play a crucial role in allowing dissemination of the correct messages regarding patient management. Also, patient compliance with healthcare providers’ guidelines could be achievable by enhanced collaboration, and long-term, trusted partnerships could also be established.

    VACCINATION

    The recent availability of vaccines to prevent SARS-CoV-2 infection has raised concerns regarding the safety and efficacy of immunization in patients with IBD. Until now, there has been international agreement among the main international IBD expert groups that the risks of SARS-CoV-2 vaccination in patients with IBD are anticipated to be very low, and it is strongly recommended that patients with IBD should be given a COVID-19 vaccine once it is widely available[2,96-98]. All coronavirus vaccines, which are licensed or in the final stages of testing, are considered suitable for patients on biologics, steroids, and immunosuppressants, as they are not live vaccines. These include the mRNA (Pfizer, Moderna), the non-replicating adenovirus vector (Oxford), and the inactivated SARS-CoV-2 (Coronavac) vaccines. Analogous to other vaccines used for many years, such as influenza and pneumonia vaccines, there is no indication of worsening IBD symptoms or flares following vaccination, and immunization appears improbable to affect IBD activity[99]. SARS-CoV-2 vaccines have also been tested in tens of thousands of patients with safety profiles analogous to other vaccines commonly used in patients with IBD, such as the flu vaccine.

    For patients under immunosuppressive treatments, it is anticipated that the vaccine may be slightly less effective, as other studies have shown that immunosuppressant medications may induce some reduction in antibody formation and lower immune response with other common vaccines. For instance, it has been demonstrated that the serologic conversion rate to influenza vaccine is lower in immunosuppressed patients with IBD[99,100]and that the immune response to pneumococcal polysaccharide vaccination is reduced in patients with CD by combining TNF-blockers and immunomodulators[101]. Conversely, treatment with newer biologics, such as ustekinumab or vedolizumab, does not seem to decrease responses to flu vaccine[102,103]. We still do not know which IBD treatments, if any, will reduce the effectiveness of the coronavirus vaccine; however, it is important to emphasize that even if the COVID-19 vaccine works slightly less well in immunosuppressed patients, it will still offer greater protection than not having the vaccine.

    It is not advisable that patients should stop their treatments to get vaccinated, as it can induce an exacerbation, putting patients at a greater risk of serious complications of COVID-19. Also, patients should avoid receiving their vaccine on the same day of an infusion/subcutaneous dose of biologic, just in the exceptional circumstance that the patient develops a reaction or adverse effect. It would be important to identify which one (vaccine or biologic) has caused it.

    CONCLUSION

    In this review, we presented a guide for the practicing clinician for managing IBD during the COVID-19 pandemic. We also reviewed the risk of infection during endoscopy, highlighting the restricted conditions where we still should indicate GI endoscopy in patients with IBD and the recommendations of the most important endoscopy societies for a safer procedure. All known or suspected COVID-19-positive patients requiring surgical intervention must be treated as positive until proven otherwise to minimize infection spread. It is not advisable that patients should stop their treatments to get vaccinated, as it can induce an exacerbation, putting patients at a greater risk of serious complications of COVID-19. In this time of an unprecedented pandemic, where knowledge about COVID-19 rapidly expands, we suggest that clinicians caring for patients with IBD should periodically check for updates in the SECURE-IBD registry and Gastroenterology Societies statements and guidelines to update knowledge about SARS-CoV-2 and COVID-19 in patients with IBD for better information and follow the approach to manage medications in IBD in this challenging context.

    男人舔女人下体高潮全视频| 国产大屁股一区二区在线视频| 国产伦精品一区二区三区视频9| 九九爱精品视频在线观看| 男女下面进入的视频免费午夜| 国产精品不卡视频一区二区| 国产片特级美女逼逼视频| 爱豆传媒免费全集在线观看| 欧美日韩综合久久久久久| 国产在视频线在精品| 久久6这里有精品| 亚洲精品日韩av片在线观看| 国产精品久久久久久久电影| 搞女人的毛片| 亚洲成色77777| 91aial.com中文字幕在线观看| 亚洲伊人久久精品综合| 免费大片18禁| 日本黄色片子视频| 亚洲精品一二三| 欧美xxⅹ黑人| 久久久久久伊人网av| 91在线精品国自产拍蜜月| 国内精品宾馆在线| 国产一区有黄有色的免费视频 | 免费观看av网站的网址| 美女国产视频在线观看| av国产久精品久网站免费入址| 少妇熟女欧美另类| 人人妻人人看人人澡| 大话2 男鬼变身卡| 亚洲av成人av| 好男人在线观看高清免费视频| 伊人久久国产一区二区| 久久久久久久久久人人人人人人| 国内揄拍国产精品人妻在线| 91精品伊人久久大香线蕉| 建设人人有责人人尽责人人享有的 | 国产精品一区二区在线观看99 | 国产人妻一区二区三区在| 极品少妇高潮喷水抽搐| 在线天堂最新版资源| 草草在线视频免费看| 欧美日韩视频高清一区二区三区二| 午夜老司机福利剧场| 国产91av在线免费观看| 久久久久久久久久久免费av| 草草在线视频免费看| 国精品久久久久久国模美| 免费看av在线观看网站| 天天一区二区日本电影三级| 精华霜和精华液先用哪个| 狂野欧美激情性xxxx在线观看| av女优亚洲男人天堂| 久久久a久久爽久久v久久| 老司机影院毛片| 日韩中字成人| 嫩草影院入口| 中文在线观看免费www的网站| 内射极品少妇av片p| 亚洲av国产av综合av卡| 免费大片18禁| 国产91av在线免费观看| 九九在线视频观看精品| 在线免费观看的www视频| 18禁在线无遮挡免费观看视频| 久久久久久久大尺度免费视频| 91精品一卡2卡3卡4卡| 国产精品综合久久久久久久免费| 精品久久久久久久久av| 免费在线观看成人毛片| 国产成人一区二区在线| 欧美日韩精品成人综合77777| av在线天堂中文字幕| 久久精品夜色国产| 久久久久免费精品人妻一区二区| 亚洲国产精品sss在线观看| 日韩强制内射视频| 国产单亲对白刺激| 岛国毛片在线播放| 亚洲国产欧美在线一区| 久久综合国产亚洲精品| 精品一区二区三区视频在线| 国产成人精品一,二区| 最近中文字幕2019免费版| 亚洲怡红院男人天堂| 搡老妇女老女人老熟妇| av线在线观看网站| 熟女电影av网| 亚洲av成人av| 在线免费观看不下载黄p国产| 免费人成在线观看视频色| 一区二区三区高清视频在线| 欧美性猛交╳xxx乱大交人| a级毛色黄片| 国产亚洲精品av在线| 午夜福利高清视频| 日韩强制内射视频| 99热这里只有精品一区| 国产精品一区二区在线观看99 | 又爽又黄无遮挡网站| 在线播放无遮挡| 亚洲精品视频女| 噜噜噜噜噜久久久久久91| 免费在线观看成人毛片| 国产黄片美女视频| 国产成年人精品一区二区| 久久久色成人| 日日摸夜夜添夜夜添av毛片| 九九久久精品国产亚洲av麻豆| 精品久久久久久久末码| 青春草视频在线免费观看| 欧美精品一区二区大全| 少妇裸体淫交视频免费看高清| 最后的刺客免费高清国语| 最近视频中文字幕2019在线8| 网址你懂的国产日韩在线| 欧美+日韩+精品| 联通29元200g的流量卡| 2021天堂中文幕一二区在线观| 亚洲精品亚洲一区二区| 国产成人91sexporn| 国产欧美另类精品又又久久亚洲欧美| 日本猛色少妇xxxxx猛交久久| 国产av不卡久久| 亚洲欧美精品专区久久| 蜜臀久久99精品久久宅男| 99视频精品全部免费 在线| 人人妻人人看人人澡| 成人综合一区亚洲| 人人妻人人看人人澡| 少妇高潮的动态图| 高清视频免费观看一区二区 | 全区人妻精品视频| 亚洲精品乱码久久久久久按摩| 亚洲精品成人久久久久久| 你懂的网址亚洲精品在线观看| 欧美高清成人免费视频www| 午夜精品一区二区三区免费看| 精品久久久久久久人妻蜜臀av| 十八禁网站网址无遮挡 | 亚洲人成网站在线观看播放| 精品少妇黑人巨大在线播放| 人人妻人人看人人澡| 国产日韩欧美在线精品| 久久久久久久久久久免费av| 你懂的网址亚洲精品在线观看| 亚洲国产精品sss在线观看| 男人舔女人下体高潮全视频| 亚洲av成人精品一二三区| 欧美精品国产亚洲| 亚洲精品久久午夜乱码| 乱系列少妇在线播放| 成年av动漫网址| 中文在线观看免费www的网站| 精品一区二区三卡| 国产精品一区二区三区四区免费观看| 免费av不卡在线播放| 午夜福利高清视频| 黄片wwwwww| 日韩av免费高清视频| av在线播放精品| 国产精品美女特级片免费视频播放器| 狠狠精品人妻久久久久久综合| 免费黄频网站在线观看国产| 亚洲三级黄色毛片| 久久久久久久亚洲中文字幕| 国产精品人妻久久久久久| 国产免费福利视频在线观看| 日日撸夜夜添| 激情 狠狠 欧美| 99久国产av精品| 免费av不卡在线播放| 国产av不卡久久| 干丝袜人妻中文字幕| 波野结衣二区三区在线| 青春草亚洲视频在线观看| 国产精品蜜桃在线观看| 一区二区三区高清视频在线| 卡戴珊不雅视频在线播放| 精品久久久噜噜| 国产精品人妻久久久影院| 女人十人毛片免费观看3o分钟| 免费看a级黄色片| 国产成人a∨麻豆精品| 别揉我奶头 嗯啊视频| 精品不卡国产一区二区三区| 国产黄a三级三级三级人| 成人漫画全彩无遮挡| 美女高潮的动态| 夫妻性生交免费视频一级片| 久久精品夜夜夜夜夜久久蜜豆| 看免费成人av毛片| av黄色大香蕉| 成年女人在线观看亚洲视频 | 国产精品久久久久久久久免| 国产在视频线在精品| 国产成人a区在线观看| 中文资源天堂在线| 国产成人精品久久久久久| 日本与韩国留学比较| 又粗又硬又长又爽又黄的视频| 丰满乱子伦码专区| 一区二区三区乱码不卡18| 亚洲国产成人一精品久久久| 91精品一卡2卡3卡4卡| 美女国产视频在线观看| 男人狂女人下面高潮的视频| 两个人的视频大全免费| 精品久久久久久久末码| 国产探花极品一区二区| 色哟哟·www| 欧美成人精品欧美一级黄| 天堂中文最新版在线下载 | 久久午夜福利片| 久久精品熟女亚洲av麻豆精品 | 亚洲精品成人av观看孕妇| av福利片在线观看| 久久99热这里只频精品6学生| 99热这里只有是精品50| 搡女人真爽免费视频火全软件| 成人性生交大片免费视频hd| 精品国产露脸久久av麻豆 | 亚洲av成人精品一区久久| 欧美日韩在线观看h| 婷婷色综合www| 亚洲在久久综合| 五月玫瑰六月丁香| 高清在线视频一区二区三区| 亚洲熟女精品中文字幕| 最近的中文字幕免费完整| 色综合色国产| 欧美一区二区亚洲| 乱码一卡2卡4卡精品| 国产黄频视频在线观看| 水蜜桃什么品种好| 国产成人精品久久久久久| av在线播放精品| av专区在线播放| 亚洲av成人精品一二三区| 一级黄片播放器| 国产高清不卡午夜福利| 一级毛片久久久久久久久女| 午夜视频国产福利| 免费不卡的大黄色大毛片视频在线观看 | 亚洲色图av天堂| 色综合站精品国产| 亚洲三级黄色毛片| 亚洲精品乱久久久久久| 欧美高清性xxxxhd video| 日韩av不卡免费在线播放| 欧美xxxx黑人xx丫x性爽| 欧美日本视频| 爱豆传媒免费全集在线观看| 伊人久久国产一区二区| 久久精品夜夜夜夜夜久久蜜豆| 99热全是精品| 一区二区三区高清视频在线| 啦啦啦中文免费视频观看日本| 免费黄频网站在线观看国产| 亚洲国产av新网站| 中文字幕免费在线视频6| 国产爱豆传媒在线观看| 插阴视频在线观看视频| 一个人看的www免费观看视频| 国产高清国产精品国产三级 | 国产精品蜜桃在线观看| 街头女战士在线观看网站| 99久久精品国产国产毛片| 亚洲欧美日韩东京热| 一级片'在线观看视频| 欧美极品一区二区三区四区| 91av网一区二区| 最近2019中文字幕mv第一页| 国产免费一级a男人的天堂| 国产精品久久视频播放| 成人午夜精彩视频在线观看| 少妇的逼好多水| 伊人久久国产一区二区| 国产一区二区在线观看日韩| 麻豆精品久久久久久蜜桃| 日本-黄色视频高清免费观看| 亚洲欧美日韩卡通动漫| 国产一区二区三区综合在线观看 | 久久99蜜桃精品久久| 国产精品久久久久久精品电影小说 | 99热全是精品| 边亲边吃奶的免费视频| 男女国产视频网站| a级毛色黄片| 小蜜桃在线观看免费完整版高清| 身体一侧抽搐| 一级a做视频免费观看| 好男人在线观看高清免费视频| 久久久精品免费免费高清| 国产黄色免费在线视频| 最近中文字幕高清免费大全6| 国产乱人偷精品视频| 天堂中文最新版在线下载 | 日韩av不卡免费在线播放| 国产视频首页在线观看| 国产精品一二三区在线看| 欧美人与善性xxx| 国产乱人视频| 又粗又硬又长又爽又黄的视频| 人妻系列 视频| 精品不卡国产一区二区三区| 国产精品久久视频播放| av福利片在线观看| 一区二区三区免费毛片| 网址你懂的国产日韩在线| 国产精品精品国产色婷婷| 精品国内亚洲2022精品成人| 777米奇影视久久| 精品久久久久久久久久久久久| 久久国产乱子免费精品| 免费看av在线观看网站| 亚洲欧美日韩无卡精品| 人妻少妇偷人精品九色| 欧美精品一区二区大全| 亚洲精品影视一区二区三区av| 在线观看人妻少妇| 精品久久久久久久末码| 国产人妻一区二区三区在| 国产一区有黄有色的免费视频 | 身体一侧抽搐| 乱人视频在线观看| 亚洲国产成人一精品久久久| 成人亚洲精品一区在线观看 | 色尼玛亚洲综合影院| 亚洲欧美一区二区三区黑人 | 国产高潮美女av| 美女xxoo啪啪120秒动态图| 极品教师在线视频| 国产黄频视频在线观看| 国产69精品久久久久777片| 午夜福利高清视频| 午夜免费激情av| 成年版毛片免费区| 毛片一级片免费看久久久久| 欧美不卡视频在线免费观看| 亚洲aⅴ乱码一区二区在线播放| 麻豆成人av视频| 乱人视频在线观看| 欧美人与善性xxx| 成人漫画全彩无遮挡| 欧美高清成人免费视频www| 久久久久久久午夜电影| 午夜视频国产福利| 床上黄色一级片| 久久久久久久亚洲中文字幕| 亚洲av成人av| 国产探花在线观看一区二区| 精品久久久久久久久av| 亚洲人成网站在线观看播放| 亚洲av电影在线观看一区二区三区 | 联通29元200g的流量卡| 麻豆国产97在线/欧美| 国产淫语在线视频| 亚洲自偷自拍三级| 国产色婷婷99| 国产国拍精品亚洲av在线观看| 国产综合懂色| 国产伦精品一区二区三区视频9| 熟妇人妻不卡中文字幕| 国产精品av视频在线免费观看| 中文字幕制服av| 免费看a级黄色片| 非洲黑人性xxxx精品又粗又长| 国产高潮美女av| 亚洲国产精品成人久久小说| 成年女人看的毛片在线观看| 在线 av 中文字幕| 国内少妇人妻偷人精品xxx网站| 国产精品久久久久久精品电影小说 | 美女高潮的动态| av在线观看视频网站免费| 午夜精品在线福利| 国内少妇人妻偷人精品xxx网站| 老司机影院成人| 午夜福利网站1000一区二区三区| 午夜福利视频精品| 99re6热这里在线精品视频| 青青草视频在线视频观看| 久久久欧美国产精品| 一级毛片电影观看| 中国美白少妇内射xxxbb| 欧美一区二区亚洲| 国内精品一区二区在线观看| 国产免费视频播放在线视频 | 亚洲四区av| 亚洲av日韩在线播放| 亚洲国产色片| 男女啪啪激烈高潮av片| 久久久久性生活片| 国产精品无大码| 欧美3d第一页| 91av网一区二区| 久久久久久久国产电影| 99久久精品热视频| 国产日韩欧美在线精品| 色综合站精品国产| 内射极品少妇av片p| 国产高清有码在线观看视频| av天堂中文字幕网| 午夜福利视频1000在线观看| 国产精品一区二区性色av| 男人爽女人下面视频在线观看| 全区人妻精品视频| 亚洲精品久久午夜乱码| 精品久久久久久久久久久久久| 18禁动态无遮挡网站| 亚洲,欧美,日韩| 国产不卡一卡二| av女优亚洲男人天堂| 少妇熟女aⅴ在线视频| 国产男人的电影天堂91| 亚洲精品456在线播放app| 国内精品美女久久久久久| 久久久久久久午夜电影| 久久精品久久精品一区二区三区| 亚洲天堂国产精品一区在线| 亚洲乱码一区二区免费版| 免费在线观看成人毛片| 麻豆久久精品国产亚洲av| 97热精品久久久久久| 欧美激情久久久久久爽电影| 免费看美女性在线毛片视频| 久久这里有精品视频免费| 亚洲av电影在线观看一区二区三区 | 日韩视频在线欧美| 91av网一区二区| 亚洲欧美一区二区三区国产| 成人亚洲精品一区在线观看 | 日日啪夜夜爽| 亚洲国产精品sss在线观看| 日韩亚洲欧美综合| 啦啦啦韩国在线观看视频| 我的老师免费观看完整版| 欧美日韩亚洲高清精品| 亚洲av成人av| 成人美女网站在线观看视频| 亚洲av.av天堂| 高清毛片免费看| 久久精品国产自在天天线| 蜜桃亚洲精品一区二区三区| 日韩精品青青久久久久久| 一区二区三区免费毛片| 亚洲色图av天堂| 观看美女的网站| 欧美高清成人免费视频www| 国产成人福利小说| 最近最新中文字幕大全电影3| 国产伦精品一区二区三区视频9| 亚洲av不卡在线观看| 亚洲精品久久久久久婷婷小说| 久久久色成人| 人体艺术视频欧美日本| 欧美zozozo另类| 特级一级黄色大片| 一夜夜www| 不卡视频在线观看欧美| 一夜夜www| 伊人久久精品亚洲午夜| 观看美女的网站| 亚洲,欧美,日韩| 搡老妇女老女人老熟妇| 国产成人一区二区在线| 日韩强制内射视频| 亚洲丝袜综合中文字幕| 日日撸夜夜添| 亚洲精品乱码久久久v下载方式| 亚洲自拍偷在线| 秋霞在线观看毛片| freevideosex欧美| 国产亚洲一区二区精品| 欧美日韩在线观看h| 亚洲成人一二三区av| 亚洲精品,欧美精品| 秋霞在线观看毛片| 国内少妇人妻偷人精品xxx网站| 毛片女人毛片| 国产精品一区二区性色av| 精品欧美国产一区二区三| 国产伦一二天堂av在线观看| 国产精品爽爽va在线观看网站| 久久久欧美国产精品| 国产黄a三级三级三级人| 精品久久久噜噜| 国产男人的电影天堂91| 中文字幕久久专区| 又粗又硬又长又爽又黄的视频| 男女那种视频在线观看| 草草在线视频免费看| 亚洲精品乱码久久久v下载方式| 日韩不卡一区二区三区视频在线| 蜜桃久久精品国产亚洲av| 精品国产三级普通话版| 丝瓜视频免费看黄片| 亚洲美女视频黄频| 亚洲国产精品国产精品| 国产成人免费观看mmmm| 国产综合懂色| 我的女老师完整版在线观看| 精品久久久噜噜| 床上黄色一级片| 国产在线男女| 久久久精品欧美日韩精品| 天堂av国产一区二区熟女人妻| 国产欧美另类精品又又久久亚洲欧美| 夜夜爽夜夜爽视频| 亚洲欧洲国产日韩| 国产在视频线在精品| 一级毛片 在线播放| 亚洲天堂国产精品一区在线| 亚洲精品乱久久久久久| 成人一区二区视频在线观看| 日本猛色少妇xxxxx猛交久久| 日韩一区二区视频免费看| 一级毛片电影观看| 国产亚洲精品av在线| 欧美性感艳星| 高清视频免费观看一区二区 | 国产69精品久久久久777片| 男女边摸边吃奶| 久久99热6这里只有精品| 亚洲国产精品sss在线观看| 国产精品蜜桃在线观看| 久久精品国产自在天天线| 欧美高清性xxxxhd video| www.色视频.com| 中文在线观看免费www的网站| 爱豆传媒免费全集在线观看| 日韩欧美国产在线观看| 七月丁香在线播放| 日韩欧美国产在线观看| 爱豆传媒免费全集在线观看| 国产欧美日韩精品一区二区| 亚洲伊人久久精品综合| 亚洲久久久久久中文字幕| 亚洲精品日韩av片在线观看| 成人鲁丝片一二三区免费| 男人舔奶头视频| 亚洲国产精品成人久久小说| 身体一侧抽搐| 亚洲精品日本国产第一区| 国产永久视频网站| 在线免费观看不下载黄p国产| 亚洲精品自拍成人| 免费黄色在线免费观看| 2021天堂中文幕一二区在线观| 久久精品久久久久久久性| 国产一区二区三区av在线| 免费看日本二区| 又大又黄又爽视频免费| 精品亚洲乱码少妇综合久久| 一级毛片 在线播放| 夜夜爽夜夜爽视频| 久久久久久国产a免费观看| 久久这里有精品视频免费| 久久久精品欧美日韩精品| 特级一级黄色大片| 免费观看无遮挡的男女| 三级男女做爰猛烈吃奶摸视频| 春色校园在线视频观看| 免费观看av网站的网址| 一级av片app| 久久人人爽人人爽人人片va| 少妇熟女aⅴ在线视频| 人妻少妇偷人精品九色| 99久久精品热视频| 日韩成人伦理影院| 日本一二三区视频观看| 日本色播在线视频| 日韩一区二区视频免费看| 亚洲高清免费不卡视频| 日产精品乱码卡一卡2卡三| 国产高清三级在线| 国产高清有码在线观看视频| 天天躁夜夜躁狠狠久久av| 直男gayav资源| 听说在线观看完整版免费高清| 欧美三级亚洲精品| 免费看av在线观看网站| 亚洲内射少妇av| .国产精品久久| 久久精品久久久久久久性| 亚洲熟妇中文字幕五十中出| 看十八女毛片水多多多| 麻豆乱淫一区二区| 亚洲精品色激情综合| 国产精品一区二区三区四区免费观看| 97精品久久久久久久久久精品| 最近最新中文字幕免费大全7| 熟妇人妻久久中文字幕3abv| 成人av在线播放网站| 国产精品av视频在线免费观看| 久久亚洲国产成人精品v| 亚洲最大成人手机在线| 欧美日韩精品成人综合77777| 欧美变态另类bdsm刘玥| 日本一二三区视频观看| 26uuu在线亚洲综合色| 久久久久久久久中文| 久久国内精品自在自线图片| 少妇丰满av| 亚洲精华国产精华液的使用体验| 亚洲最大成人手机在线| 热99在线观看视频| 国产成人一区二区在线| 国产淫片久久久久久久久| 亚洲国产精品专区欧美| 在线播放无遮挡| 中文乱码字字幕精品一区二区三区 | 午夜福利视频1000在线观看|